GenFleet Therapeutics

2595 · HKEX

Public Market Listing

2595HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for GenFleet Therapeutics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
KRAS G12DSmall molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Fulzerasib(Dupert)
Phase 2
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
pan-RASSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(15 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (9)
April 2027 (1)
GFH375Phase 2NSCLC (Advanced Non-small Cell Lung Cancer)
Est. primary completion 2027-04-30 · NCT07554859 · CT.gov ↗
What to watch
June 2027 (4)
GFH375Phase 2Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Est. primary completion 2027-06 · NCT07644559 · CT.gov ↗
What to watch
GFH375Phase 2Non-Small Cell Lung Cancer
Est. primary completion 2027-06 · NCT07659782 · CT.gov ↗
What to watch
GFH375Phase 2Colorectal Cancer
Est. primary completion 2027-06 · NCT07659795 · CT.gov ↗
What to watch
GFH375Phase 3Metastatic Pancreatic Cancer
Est. primary completion 2027-06 · NCT07262567 · CT.gov ↗
What to watch
July 2027 (2)
GFH375Phase 1/2Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
Est. primary completion 2027-07 · NCT07259590 · CT.gov ↗
What to watch
GFH276Phase 1/2Cancer, PDAC, CRC (Colorectal Cancer), NSCLC
Est. primary completion 2027-07-30 · NCT07198321 · CT.gov ↗
What to watch
November 2027 (1)
GFH276Phase 1/2Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
Est. primary completion 2027-11 · NCT07678593 · CT.gov ↗
What to watch
December 2027 (1)
GFH276Phase 1/2RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-12 · NCT07846358 · CT.gov ↗
What to watch
2028 (5)
April 2028 (1)
GFH276Phase 1/2CRC
Est. primary completion 2028-04-30 · NCT07915921 · CT.gov ↗
What to watch
July 2028 (1)
GFH375Phase 1/2KRAS G12D Mutations, Advanced Solid Tumors
Est. primary completion 2028-07-31 · NCT06500676 · CT.gov ↗
What to watch
August 2028 (1)
GFH375 + GFH276Phase 2Pancreatic Cancer
Est. primary completion 2028-08-31 · NCT07784374 · CT.gov ↗
What to watch
November 2028 (1)
GFH375Phase 3Colorectal Cancer
Est. primary completion 2028-11 · NCT07913360 · CT.gov ↗
What to watch
December 2028 (1)
GFH375Phase 1/2Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
GFH375Phase 3KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)
Est. primary completion 2030-06-30 · NCT07668752 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$12M——$96Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$14M$46M—$94Mreport ↗

GenFleet Therapeutics reported revenue of $14.47M, up 38.2% YoY, R&D spend of $46.21M, up 4.3% YoY, and a quarterly net burn of $94.31M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$10M$44M—$72Mreport ↗